Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.59 EUR | +0.95% |
|
+5.76% | +42.64% |
12:30pm | Bayer Seeks EU Approval for Low-Dose MRI Contrast Agent Gadoquatrane | MT |
12:04pm | Bayer files for EU approval of gadoquatrane | RE |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | -1.05TCr | 100Cr | 415Cr | -294.1Cr | -255.2Cr | |||||
Depreciation & Amortization - CF | 162.3Cr | 149.2Cr | 154.5Cr | 159.3Cr | 159.5Cr | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 182.1Cr | 12Cr | 240.4Cr | 231.6Cr | 245.4Cr | |||||
Depreciation & Amortization, Total | 344.4Cr | 160.9Cr | 394.9Cr | 390.9Cr | 404.9Cr | |||||
(Gain) Loss From Sale Of Asset | -13Cr | -22Cr | -169.2Cr | -15Cr | -21Cr | |||||
Asset Writedown & Restructuring Costs | 981.5Cr | 144.7Cr | 255.4Cr | 611.1Cr | 473.4Cr | |||||
Net Cash From Discontinued Operations | 33Cr | - | - | - | - | |||||
Other Operating Activities, Total | -673.7Cr | 19Cr | 83Cr | 225.5Cr | 125.9Cr | |||||
Change In Accounts Receivable | 70Cr | -6.1Cr | 27Cr | 69Cr | 20Cr | |||||
Change In Inventories | -90Cr | -17Cr | -217Cr | -43Cr | 52Cr | |||||
Change In Accounts Payable | -35Cr | 85Cr | 61Cr | 8.2Cr | -12Cr | |||||
Change in Other Net Operating Assets | 922Cr | 44Cr | -140.7Cr | -440.6Cr | -51Cr | |||||
Cash from Operations | 490.3Cr | 508.9Cr | 709.3Cr | 511.7Cr | 736.8Cr | |||||
Capital Expenditure | -241.8Cr | -261.1Cr | -294.9Cr | -275.1Cr | -277.8Cr | |||||
Sale of Property, Plant, and Equipment | 33Cr | 37Cr | 113Cr | 22Cr | 30Cr | |||||
Cash Acquisitions | -226.3Cr | -134Cr | -8.9Cr | -66Cr | -18Cr | |||||
Divestitures | 417.2Cr | -60L | 228.7Cr | 80L | 1.7Cr | |||||
Investment in Marketable and Equity Securities, Total | -402.7Cr | 430.2Cr | -297.8Cr | -31Cr | 232.5Cr | |||||
Other Investing Activities, Total | 13Cr | 14Cr | 22Cr | -2.1Cr | 49Cr | |||||
Cash from Investing | -407.3Cr | 86Cr | -238.1Cr | -351.7Cr | 16Cr | |||||
Long-Term Debt Issued, Total | 1.09TCr | 659.2Cr | 663.1Cr | 1.63TCr | 581.5Cr | |||||
Total Debt Issued | 1.09TCr | 659.2Cr | 663.1Cr | 1.63TCr | 581.5Cr | |||||
Long-Term Debt Repaid, Total | -642.4Cr | -904.4Cr | -760.5Cr | -1.3TCr | -1.08TCr | |||||
Total Debt Repaid | -642.4Cr | -904.4Cr | -760.5Cr | -1.3TCr | -1.08TCr | |||||
Issuance of Common Stock | - | - | - | 2.3Cr | - | |||||
Repurchase of Common Stock | - | - | -1Cr | -2.4Cr | -1.6Cr | |||||
Common Dividends Paid | -275.1Cr | -199.3Cr | -198.5Cr | -237.9Cr | -11Cr | |||||
Common & Preferred Stock Dividends Paid | -275.1Cr | -199.3Cr | -198.5Cr | -237.9Cr | -11Cr | |||||
Other Financing Activities, Total | -129.3Cr | -120Cr | -125.1Cr | -155.2Cr | -203.6Cr | |||||
Cash from Financing | 42Cr | -564.5Cr | -422Cr | -68Cr | -717.8Cr | |||||
Foreign Exchange Rate Adjustments | -24Cr | 3.5Cr | 11Cr | -18Cr | -6.8Cr | |||||
Miscellaneous Cash Flow Adjustments | -70L | 3.9Cr | 30L | - | -20L | |||||
Net Change in Cash | 100.6Cr | 37Cr | 61Cr | 74Cr | 28Cr | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 130.1Cr | 122.7Cr | 129.6Cr | 153.7Cr | 197.7Cr | |||||
Cash Income Tax Paid (Refund) | 106.3Cr | 215.9Cr | 203.4Cr | 177Cr | 122.2Cr | |||||
Levered Free Cash Flow | 1.48TCr | -138.24Cr | 584.74Cr | 151.86Cr | 371.61Cr | |||||
Unlevered Free Cash Flow | 1.58TCr | -58Cr | 650.86Cr | 222.74Cr | 493.24Cr | |||||
Change In Net Working Capital | -1.04TCr | 423.4Cr | 56Cr | 395.8Cr | -162.4Cr | |||||
Net Debt Issued / Repaid | 446.7Cr | -245.2Cr | -97Cr | 325.3Cr | -501.8Cr |
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition